Aegis Capital reiterated coverage on SCYNEXIS with a new price target

4/12/21 12:54:40 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Aegis Capital reiterated coverage of SCYNEXIS with a rating of Buy and set a new price target of $40.00 from $45.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SCYX

Date	Price Target	Rating	Analyst